Table 1 Baseline characteristics of the total population
|  | Total population | NODM (+) (n = 40) | NODM (−) (n = 281) | P value |
|---|---|---|---|---|
Demographic findings | ||||
 Age (years) | 60 (51, 69) | 60 (51, 72) | 59 (51, 69) | 0.950 |
 Sex (male, %) | 238 (74.1%) | 30 (75.0%) | 208 (74.0%) | 0.895 |
 BMI (kg/m2) | 24.9 (23.2, 27.1) | 25.8 (23.7, 28.0) | 24.8 (23.2, 27.0) | 0.184 |
 BMI > 25 kg/m2 | 157 (48.9%) | 23 (57.5%) | 134 (47.7%) | 0.245 |
 Clinical diagnosis (%) | 0.984 | |||
  Stable angina | 115 (35.8%) | 14 (35.0%) | 101 (35.9%) |  |
  Unstable angina | 48 (15.0%) | 7 (17.5%) | 41 (14.6%) |  |
  NSTEMI | 64 (19.9%) | 7 (17.5%) | 57 (20.3%) |  |
  STEMI | 94 (29.3%) | 12 (30.0%) | 82 (29.2%) |  |
 Hypertension (%) | 127 (39.6%) | 19 (47.5%) | 108 (38.4%) | 0.273 |
 Current smoking (%) | 84 (26.2%) | 10 (25.0%) | 74 (26.3%) | 0.857 |
 Previous CVA (%) | 11 (3.4%) | 0 (0.0%) | 11 (3.9%) | 0.203 |
 Bronchial asthma (%) | 5 (1.6%) | 1 (2.5%) | 4 (1.4%) | 0.607 |
 COPD (%) | 9 (2.8%) | 2 (5.0%) | 7 (2.5%) | 0.368 |
 Dyslipidemia (%) | 80 (24.8%) | 9 (22.5%) | 71 (25.3%) | 0.705 |
 Prediabetes (%) | 130 (40.5%) | 31 (77.5%) | 99 (35.2%) | < 0.001 |
Laboratory findings | ||||
 WBC (/μL) | 7900 (5970, 10,950) | 7640 (5500, 10,450) | 7900 (6000, 11,040) | 0.589 |
 Hemoglobin (g/dL) | 14.6 (13.5, 15.6) | 15.0 (13.6, 15.8) | 14.5 (13.4, 15.6) | 0.246 |
 Fasting blood glucose (mg/dL) | 92 (84, 103) | 98 (90, 107) | 92 (84, 102) | 0.010 |
 HbA1c (%/mmol/mol) | 5.7 (5.5, 5.9)/38.8 (36.6, 41.0) | 6.0 (5.7, 6.3)/42.1 (39.1, 45.4) | 5.7 (5.4, 5.8)/38.8 (35.5, 39.9) | < 0.001 |
 Total cholesterol (mg/dL) | 207 (177, 240) | 210 (171, 246) | 207 (179, 240) | 0.774 |
 Triglyceride (mg/dL) | 133 (90, 209) | 145 (99, 214) | 131 (89, 209) | 0.414 |
 HDL-cholesterol (mg/dL) | 42 (37, 50) | 40 (35, 47) | 43 (37, 51) | 0.100 |
 LDL-cholesterol (mg/dL) | 133 (110, 157) | 126 (112, 157) | 133 (108, 157) | 0.979 |
 Serum creatinine (mg/dL) | 0.88 (0.73, 1.01) | 0.84 (0.76-1.00) | 0.98 (0.73, 1.02) | 0.524 |
 hsCRP (mg/dL) | 0.15 (0.10, 0.31) | 0.15 (0.10, 0.25) | 0.15 (0.10, 0.32) | 0.264 |
Echocardiography | ||||
 LVEDD (mm) | 48.0 (44.3, 51.9) | 49.0 (45.0, 52.1) | 48.0 (44.0, 51.9) | 0.408 |
 LVESD (mm) | 31.0 (27.0, 35.0) | 32.0 (29.0, 34.6) | 30.3 (26.9, 35.1) | 0.319 |
 LV ejection fraction (%) | 60.0 (53.5, 64.7) | 60.3 (54.9, 66.1) | 59.5 (53.1, 64.5) | 0.246 |
 Left atrium dimension (mm) | 37.1 (33.7, 41.0) | 36.8 (34.1, 40.0) | 37.4 (33.7, 41.0) | 0.624 |
  EAT diastole (mm) | 1.4 (1.0, 2.2) | 2.2 (1.4, 3.5) | 1.2 (1.0, 2.1) | < 0.001 |
  EAT systole (mm) | 4.0 (3.0, 4.9) | 5.4 (4.2, 7.4) | 3.9 (2.9 4.8) | < 0.001 |
Baseline medication | ||||
 Aspirin | 321 (100%) | 40 (100%) | 281 (100%) | NA |
 Clopidogrel | 320 (99.7%) | 40 (100%) | 280 (99.6%) | 0.706 |
 ACE inhibitor or ARB | 275 (85.7%) | 34 (85.0%) | 241 (85.8%) | 0.897 |
 Beta blockers | 246 (76.6%) | 30 (75.0%) | 216 (76.9%) | 0.794 |
 Thiazides | 36 (11.2%) | 4 (10.0%) | 32 (11.4%) | 0.795 |
 Systemic steroid | 30 (9.3%) | 3 (7.5%) | 27 (9.6%) | 0.668 |
Statin | 0.128 | |||
  Atorvastatin 40 mg | 204 (63.6%) | 20 (50.0%) | 184 (65.5%) |  |
  Atorvastatin 80 mg | 57 (17.8%) | 11 (27.5%) | 46 (16.4%) |  |
  Rosuvastatin 20 mg | 60 (18.7%) | 9 (22.5%) | 51 (18.1%) |  |
Statin duration (days) | ||||
  Total statin duration | 1248 (984, 1800) | 1348 (983, 1827) | 1237 (984, 1800) | 0.293 |
  High intensity statin duration | 930 (541, 1216) | 963 (785, 1322) | 922 (500, 1210) | 0.297 |